A 6-Month Extension Study of OTO-104 in Meniere's Disease
Stopped early · Phase 3
Conditions studied: Meniere's Disease
In brief
This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201102 (Phase 2b study of OTO-104) or 104-201506 (Phase 3 study of OTO-104) in order to be eligible for this open-label extension study.
Key facts
- Study ID
- NCT02706730
- Run by
- Otonomy, Inc.
- People needed
- 189
- Starts
- 2016-02-01
- Expected to finish
- 2017-09-01
- Last updated by the study team
- 2022-12-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Many sites in US. Refer to the contact info listed below. — San Diego, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.